SCM
DNLI icon

Soleus Capital Management’s Denali Therapeutics DNLI Stock Holding History

Soleus Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-182,110
Closed -$2.55M – 95
2025
Q2 		$2.55M Buy
182,110
+47,110
+35% +$663K 0.17% 72
2025
Q1 		$1.84M Buy
+135,000
New +$2.59M 0.13% 64
2024
Q2 		– Sell
-47,000
Closed -$964K – 98
2024
Q1 		$964K Sell
47,000
-83,000
-64% -$1.56M 0.07% 83
2023
Q4 		$2.79M Buy
+130,000
New +$2.57M 0.31% 50

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Soleus Capital Management's DNLI Position: Q3 2025 in Review

Soleus Capital Management sold out of Denali Therapeutics (DNLI) in Q3 2025, closing a stake of 182,110 shares — an estimated $2.55M sold.

Soleus Capital Management first reported a position in DNLI in Q4 2023 and held it in 4 quarters. The position peaked at $2.79M in Q4 2023. 240 funds tracked by Wall St. Rank hold DNLI as of Q3 2025.

  • Soleus Capital Management reported no remaining Denali Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Soleus Capital Management sold 182,110 Denali Therapeutics shares in Q3 2025, an estimated $2.55M.
  • Soleus Capital Management first reported a position in Denali Therapeutics in Q4 2023 and held it in 4 quarters.
  • Soleus Capital Management's Denali Therapeutics position peaked at $2.79M in Q4 2023.
  • 240 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2025.

Based on Soleus Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.